1. Pink Sheet
  2. >>Archive

Janssen 340B Discount Growth Slowed In 2022 But Still Topped $6bn; Patient Assistance Jumps 24%

 
• By Cathy Kelly

Janssen continues to pursue aggressive policies to reduce inappropriate use of 340B discounts. Firm estimates that 58% of list prices went to commercial and government insurers, 340B providers and others in the US health care system in the form of price concessions last year.

340B Discounts Was The Only Category To Decrease Compared To 2021 • Source: Shutterstock

Janssen Pharmaceuticals Inc.’s efforts to staunch the flow of its price concessions under the 340B program contributed to a relatively small decline in the discounts in 2022 – from $6.4bn in 2021 to $6.2bn – according to the company’s recently released US pricing transparency report for the year.

Key Takeaways

  • Janssen's 340B discounts totaled $6.2bn in 2022, down from $6.4bn in 2021.

  • Stricter restrictions on 340B providers likely to slow growth further in 2023.

    ...

But the 340B program remained the second largest recipient of Janssen’s price concessions in the US, representing 16% of all of the company’s discounts and rebates in 2022. That share...

More from Archive

More from Pink Sheet

EMA: ‘Sad To See’ Member States Against Patient Engagement Under EU Pharma Reform

 
• By Eliza Slawther

The European Medicines Agency’s chief medical officer Steffen Thistrup argued that patients are able to understand the “complex regulatory and scientific issues” that the EMA committees discuss when they assess drugs.

EU To Track Decentralized Clinical Trials In CTIS To Support Innovation

 
• By Vibha Sharma

Monitoring the use of decentralized elements in clinical trials is a priority for the European medicines regulatory network.

Why Hympavzi Secured English Funding For Hemophilia B But Not Hemophilia A

 
• By Neena Brizmohun

Pfizer told the Pink Sheet it would work with the health technology assessment institute, NICE, with the hope of making Hympavzi available to patients with hemophilia A via the National Health Service.